Moderna says it plans to start phase 3 #COVID19 vaccine trial in thousands of people in July, with phase 2 of 600 people expected to start soon (1)
Moderna’s plan to expedite clinical development of #COVID19 vaccine: start phase 2 with safety data from phase 1; phase 3 with safety of phase 2 + efficacy data from phase 1 to guide dose selection (2) 
Moderna’s phase 2 #COVID19 vaccine trial will enroll 600 people and test doses of 50 and 100 micrograms; the planned high dose was revised (from 250 micrograms) based on phase 1 results (3)
Moderna’s CMO Tal Zaks notes using lower high dose for ph 2 #COVID19 vaccine trial, in addition to being guided by safety/efficacy, also reflects manufacturing capacity: “We expect demand to outstrip supply, and the lower the dose” (the more people we will be able to supply) (4)
Moderna CEO Stephane Bancel: “We are currently scaling up manufacturing capacity as fast as we can.” 1B dose/year goal of #COVID19 vaccine with Lonza is based on 50 microgram dose. “It’s going to take several quarters to get there,” Bancel says. (5)
